Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04148001|
Recruitment Status : Active, not recruiting
First Posted : November 1, 2019
Last Update Posted : April 22, 2020
|Condition or disease|
|Homozygous Familial Hypercholesterolemia (HoFH)|
This is a non-interventional study; no investigational product is administered in this study. Information collected in this study may be used to identify potential participants for clinical gene therapy trials in HoFH.
The investigator will discuss the study with participants who have a clinical presentation consistent with HoFH and where possible, the treating physician, in order to assess their interest to participate. After informed consent has been obtained, participants will be asked to provide a blood sample (up to 40 mL) for genotyping to confirm genetic diagnosis of HoFH due to mutations in LDLR, a lipid panel and anti-AAV8 NAb titer. Participants and, whenever possible, their treating physician will complete a medical history questionnaire and provide supporting documentation. The informed consent form (ICF) and data collection methods may vary depending whether the informed consent is obtained remotely or at a participating study site.
Information collected will include the following:
- patient demographics (age, sex, weight)
- medical history
- previous genotype results (if available)
- results of most recent lipid panel(s)
- use of lipid lowering therapies, including failure to respond
- assessment of presence of liver disease, including history of hepatitis B and C, human immunodeficiency virus (HIV), cirrhosis, and alcohol use
Once this information is received by the investigator and Sponsor, a preliminary assessment of confirmation of a diagnosis of HoFH will be performed. Participants and/or their treating physician will be informed of the results of the genetic testing. All participants will be provided an opportunity to speak with a genetic counselor upon receiving the results of the genetic testing.
Data collected in this study may be used to identify potential candidates for separate clinical trial(s) using gene therapy.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Clinical and Laboratory Assessment Study of Patients With a Clinical Presentation Consistent With Homozygous Familial Hypercholesterolemia (HoFH)|
|Actual Study Start Date :||December 4, 2019|
|Estimated Primary Completion Date :||December 30, 2020|
|Estimated Study Completion Date :||December 30, 2020|
- The number of participants who have HoFH due to mutations in the LDLR gene measured by genetic testing [ Time Frame: baseline ]The number of participants who have HoFH due to mutations in the LDLR (low density lipoprotein receptor) gene as confirmed by genetic testing.
- The measurement of AAV8 NAb titers [ Time Frame: baseline ]The measurement of anti-AAV8 (adeno-associated virus serotype 8) neutralizing antibody (NAb) titers
- The measurement of LDL-C, total cholesterol, very low density lipoprotein cholesterol (VLDL-C), non-high density lipoprotein cholesterol (non-HDL-C), high density lipoprotein cholesterol (HDL-C), triglycerides (TG), and lipoprotein a (Lp[a]) [ Time Frame: baseline ]The measurement of LDL-C, total cholesterol, very low density lipoprotein cholesterol (VLDL-C), non-high density lipoprotein cholesterol (non-HDL-C), high density lipoprotein cholesterol (HDL-C), triglycerides (TG), and lipoprotein a (Lp[a]).
- The number and types of the participant's current and historical lipid lowering therapies [ Time Frame: baseline ]The number and types of lipid lowering therapies, including LDL-C apheresis, the participant has been on or is currently on
- The participant's completion of the medical history questionnaire to determine relevant medical history [ Time Frame: baseline ]Collection of the participant's relevant medical history
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04148001
|United States, Florida|
|Excel Medical Clinical Trials, LLC|
|Boca Raton, Florida, United States, 33434|